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Background: Autism spectrum disorders (ASD) are much more common in males than in females. Molecular
alterations within the estrogen receptor (ER) signaling pathway may contribute to the sex difference in ASD, but
the extent of such abnormalities in the brain is not known.
Methods: Postmortem middle frontal gyrus tissues (13 ASD and 13 control subjects) were used. The protein levels
were examined by western blotting. The gene expression was determined by qRT-PCR.
Results: Gene expression analysis identified a 35% decrease in ERβ mRNA expression in the middle frontal gyrus of
ASD subjects. In addition, a 38% reduction in aromatase (CYP19A1) mRNA expression was observed in ASD subjects.
We also found significant decreases in ER co-activators that included a 34% decrease in SRC-1, a 77% decrease in
CBP, and a 52% decrease in P/CAF mRNA levels in ASD subjects relative to controls. There were no differences in
the mRNA levels of TIF-2, AIB-1 (ER co-activators), ER co-repressors (SMRT and nCoR) and ERα in the middle frontal
gyrus of ASD subjects as compared to controls. We observed significant correlations between ERβ, CYP19A1, and
co-activators in the study subjects. Immunoblot analysis further confirmed the changes in ERβ and aromatase at the
protein level in the control and ASD subjects.
Conclusions: These results, for the first time, provide the evidence of the dysregulation of ERβ and co-factors in the
brain of subjects with ASD.
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Autism spectrum disorders (ASD) are a heterogeneous set
of neurodevelopmental disorders including autism, Asper-
ger’s syndrome, childhood disintegrative disorder, and
pervasive developmental disorder not otherwise specified
(PDD-NOS). Autism is currently diagnosed by extensive
behavioral and psychological testing and diagnosis is de-
clared based on DSM-V characteristics. These characteris-
tics include communication deficits, excessive dependence
on routine, and obsessive tendencies showing up in early
childhood. ASDs are more prevalent in boys than in girls,* Correspondence: apillai@gru.edu
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unless otherwise stated.with ratios of 3:1 for classic autism and 10:1 for Asperger
syndrome, suggesting the possible role of sex hormones in
the pathophysiology of this disorder [1]. It has been sug-
gested that high levels of testosterone during early devel-
opment may be a risk factor for ASDs [2,3]. The above
hypothesis has been supported by a number of studies
reporting an association between fetal testosterone levels
and autistic features [2].
Estradiol, the most potent estrogen, is formed from
testosterone by the enzyme aromatase, also known as
cytochrome P450, family 19 (CYP19A1). Estrogen is
neuroprotective and plays an important role in emo-
tional responses [4] and in frontal cortical activity dur-
ing cognitive task performance in humans [5]. Estrogen
acts through the binding to its receptor called estrogentd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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http://www.molecularautism.com/content/5/1/46receptor (ER). ER exists in two main forms, ERα and
ERβ, which have distinct tissue expression patterns [6].
ERα and ERβ are encoded by separate genes, ESR1 and
ESR2, respectively, found at different chromosomal lo-
cations, and numerous mRNA splice variants exist for
both receptors in both diseased and normal tissue [7].
In the “classical” pathway of estrogen action, estrogen
binds to ER, a ligand-activated transcription factor that
regulates transcription of target genes in the nucleus by
binding to estrogen response element regulatory se-
quences in target genes and recruiting co-regulatory
proteins such as co-activators or co-repressors. The
major co-regulators involved in estrogen signaling are
steroid receptor co-activator 1 (SRC-1), transcriptional
mediators/intermediary factor 2 (TIF-2), nuclear re-
ceptor co-repressor 1 (nCoR), CREB-binding protein
(CBP), p300/CREB-binding protein-associated protein
(P/CAF), amplified in breast 1 (AIB-1), and silencing
mediator of retinoid and thyroid hormone receptors
(SMRT) [8]. Among these co-factors, SRC-1, TIF-2,
CBP, AIB-1, and P/CAF are transcriptional co-activators,
whereas SMRT and nCoR are transcriptional repressors.
On the other hand, in the rapid or “non-genomic” path-
way, activation of the membrane ER by estrogen leads
to a rapid change in various intracellular signaling mol-
ecules including kinases, which in turn regulate gene
transcription [9].
ERα is widely distributed in the various brain regions
including amygdala-hippocampal area, periamygdaloid
cortex, and posterior cortical nucleus of the brain [10].
Moreover, ERα influences various neurotransmitter sys-
tems, such as dopamine, serotonin (5-HT), and norepin-
ephrine, indicating its role in neuropsychiatric disorders
[11,12]. ERβ is the principal estrogen receptor expressed
in brain areas such as cerebral cortex, hippocampus, and
cerebellum [13]. An earlier study has found a significant
association of the ERβ gene with scores on the Autism
Spectrum Quotient and the Empathy Quotient in ASD
subjects [14]. Moreover, ERβ mediates some of the ef-
fects of estrogens on anxiety, locomotor activity, fear re-
sponses, and learning behavior [15]. Although the above
studies are interesting, it is still unclear whether the ex-
pression of ER is impaired in the brain of ASD subjects.
In the present study, we first examined the gene ex-
pression of ERα, ERβ, CYP19A1, and the co-regulators
SRC-1, TIF-2, CBP, P/CAF, SMRT, AIB-1, and nCoR in
postmortem middle frontal gyrus of ASD and control
subjects. The middle frontal gyrus region was selected
because a number of studies from neurocognitive as well
as neuroimaging studies have implicated middle frontal
gyrus in the pathophysiology of ASD [16-18]. Moreover,
a sexual dimorphic nature has been reported in the mid-
dle frontal gyrus [19]. Based on our mRNA data, we
then used western blotting to examine whether thechanges found at the gene level of ERβ and CYP19A1
are significant at the protein level. We hypothesized that
the expression of ERs are impaired in ASD and these ab-




The Georgia Regents University Institutional Review
Board has deemed this study exempt from full review
due to the use of de-identified human postmortem brain
samples, with no possibility to track back the identity of
the donors. There was no involvement of animal studies
in this paper.
Postmortem brain tissues
Postmortem middle frontal gyrus tissues of ASD (n = 13)
and control (n = 13) subjects were received from the
NICHD Brain and Tissue Bank for Developmental Dis-
orders at the University of Maryland, Baltimore, MD,
USA. Table 1 shows a detailed description on the demo-
graphics of samples. The individual scores for each of
the symptomatic domains, Autism Diagnostic Interview-
Revised (ADI-R) were obtained from the brain bank
website. The information on ADI-R was available for 9
out of 13 subjects with ASD. We did not find any signifi-
cant difference in confounding variables such as PMI,
refrigeration interval, age at death, RNA integrity, and
brain pH between ASD and control subjects.
Immunoblotting
Brain tissue was homogenized in a tissue lysis buffer con-
taining 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1.0% so-
dium deoxycholate, 0.1% sodium dodecyl sulfate (SDS),
2 mM EDTA, 6 μM PMSF, and 1.0% Triton X-100 supple-
mented with protease inhibitor cocktail (Sigma). The
homogenate was centrifuged at 13,000 rpm for 10 min at
4°C and the supernatant was used for protein estimation
by the bicinchoninic acid method (BCA Protein Assay Kit,
Sigma). Samples (30–40 μg) were subjected to SDS-PAGE
and transferred onto a nitrocellulose membrane. The
membrane was blocked for 1 h in PBS with Tween 20 and
5% non-fat milk or 5% BSA followed by overnight incuba-
tion with a primary antibody. The primary antibodies used
were: anti-ERβ (1:2,000, Abcam; ab3577 [20,21]; anti-ERα
(1:500, Santa Cruz Biotech; sc-71064); anti-aromatase
(1:500, Santa Cruz Biotech; sc-14245); anti-CBP (1:200,
Santa Cruz Biotech; sc-7300); anti-SRC-1 (1:500, Santa
Cruz Biotech; sc-32789), or anti-P/CAF (1:500, Santa Cruz
Biotech; sc-13124). Following washing, the membranes
were incubated with secondary antibody for 1 h. We
used enhanced chemiluminescence detection reagent
kit (Thermo Scientific) to detect the proteins. The in-
tensity of the bands was quantified using densitometry
Table 1 Demographic characteristics of postmortem brain samples
Variable Control ASD
Age (years) 11.70 ± 1.584 11.80 ± 1.609
PMI (h) 14.46 ± 2.171 19.00 ± 2.776
Sex (F/M) 1/12 0/13
Storage (days) 4287 ± 638.7 2829 ± 397.7
RIN 5.55 ± 0.71 6.84 ± 0.53
pH 5.95 ± 0.06 6.11 ± 0.07
Manner of death Drowning (3), Vehicle accident (4), Hanging/suicide (2),








Medications* Yes (1) (Concerta, Clonidine) Yes (4) (Zyprexa (1), Reminyl (1), Naltrexone (1), Risperdal (2),
Luvox (1), Clonidine (1), Insulin (1))
No (12)
No (9)
ASD, Autism spectrum disorder; F, Female; M, Male; PMI, Postmortem interval; RIN, RNA integrity; TSS, Toxic shock syndrome. Values are Mean ± SE. *Note that
some individuals took multiple medications.
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http://www.molecularautism.com/content/5/1/46software (Image J, NIH). The immunoblot data was cor-
rected for corresponding glyceraldehyde 3-phosphate
dehydrogenase (GAPDH; 1:5,000, Cell Signaling) values.
For immunoprecipitation, 300 μg of proteins were pre-
cleared for 2 h with 40 μL of PureProteome Protein A
and G Magnetic Beads (Millipore) and 40 μg IgG anti-
body (Millipore), followed by incubation overnight with
the primary antibody. The immunoprecipitated proteins
were subjected to immunoblotting for the detection of
co-precipitated proteins.
Quantitative reverse transcriptase PCR (qRT-PCR)
Total RNA from postmortem brain tissues was isolated
using a commercially available kit (SV RNA Isolation,
Promega, Madison, WI, USA). qRT-PCR was performed
on a MasterCycler (Eppendorf ) using a SuperScript III
Platinum SYBR Green One-Step qRT-PCR kit (Invitro-
gen, Carlsbad, CA, USA). A typical reaction mixture of a
total volume of 25 μL consisted of 0.5 μL Superscript III
RT/Platinum Taq mix, 12.5 μL 2X SYBR Green Reaction
Mix (includes 0.4 mM of each dNTP and 6 mM MgSO4),
12.5 pMol of each of forward or reverse primers, and 4 μL
DEPC-treated water. PCR amplification was done with an
initial incubation at 55°C for 1,200 sec, then at 95°C for
120 sec followed by 35 cycles of 95°C for 15 sec, 50°C for
30 sec, 72°C for 30 sec, and a final melting curve from
55°C to 95°C at 0.2°C/sec. We confirmed the primer speci-
ficity by melting curve analysis and electrophoresis of PCR
products on a 2% agarose gel to confirm the presence of a
single band of the predicted size. The mRNA for genes of
interest was normalized to two control genes (GAPDH
and β-actin) and a geometric mean of these genes. ThemRNA expression levels were quantified by the delta-delta
Ct method. Primers were synthesized by Integrated DNA
Technologies (Additional file 1: Table S1).
Statistical analysis
Analysis of covariance (ANCOVA) models were used to
examine the differences in estrogen receptor expression
between postmortem samples of people with ASD and
the control sample (i.e., affection status). To examine
the unique effects of affection status on estrogen recep-
tor, age, postmortem interval, storage time, sample pH,
and RNA integrity number were added to the model as
covariates. Only covariates with at least small associa-
tions with an estrogen receptor expression were consid-
ered for inclusion in the ANCOVA model with the
receptor signal as a dependent variable. Candidate covar-
iates that were significantly correlated with receptor ex-
pression levels were included in the model. To maximize
the observed power, non-significant covariates were re-
moved from the model until only significant covariates
remained in the model; η2 and partial η2 coefficients
were computed as estimates of effect size. Exact prob-
ability (P) values of less than 5% were considered signifi-
cant. Simple correlations were computed to examine the
association of covariates and clinical variables with re-
ceptor expression levels. All analyses were performed
using SPSS Statistics 20 software (IBM).
Results
The postmortem sample comprised 26 subjects, half of
whom had a confirmed diagnosis of an ASD and half of
whom were age- and gender-matched controls.
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http://www.molecularautism.com/content/5/1/46Decrease in mRNA levels of ERβ and CYP19A1, but no
change in ERα mRNA in the middle frontal gyrus of ASD
subjects
The mRNA levels of ERα, ERβ, and CYP19A1 in the mid-
dle frontal gyrus of control and ASD subjects were deter-
mined by qRT-PCR. Additional file 2: Table S2 depicts the
correlations between the mRNA transcripts and confound-
ing variables. An ANCOVA [between-subjects factor: af-
fection status (ASD, Control); covariates: age, postmortem
interval, storage time, sample PH] was performed in ERα
data analysis. None of these covariates demonstrated sig-
nificant main effects in the prediction of ERα expression.
The main effect of affection status on ERα was not statisti-
cally significant (Figure 1A) [F(1, 19) = 2.65, P = 0.12, η2p =
0.123]. We found a statistically significant main effect
of affection status on ERβ mRNA levels when age, stor-
age time, and RNA integrity number were considered
in the model as covariates (Figure 1B) [F(1, 20) = 34.10,
P <0.0001, η2p = 0.630]. None of the covariates demon-
strated a significant main effect on ERβ mRNA. Subjects
with ASD (estimated marginal means (EMM) = 65.85,
standard error (SE) = 4.06) demonstrated much lower ex-
pression (35% decrease) of ERβ than the control group
(EMM= 100.59, SE = 3.88). For CYP19A1 mRNA data
analysis, age, storage time, sample pH, RNA integrity
number, and postmortem interval were entered into theFigure 1 Decrease in mRNA levels of ERβ and CYP19A1, but no chang
(A) No significant change in ERα mRNA. (B) Significant reduction in ERβ m
lower in the ASD subjects. mRNA levels were determined by qRT-PCR, and
genes (GAPDH and β-actin). ***P <0.001 vs. controls.model as covariates. None of the covariates in the model
demonstrated a significant main effect in the prediction of
CYP19A1 mRNA when they were entered in the model
with affection status. Affection status was a significant pre-
dictor of CYP19A1 expression (Figure 1C) [F(1, 17) =
27.90, P <0.0001, η2p = 0.621]. Subjects with ASD had re-
duced (EMM= 62.76, SE = 4.78) CYP19A1 mRNA levels
(38% decrease) relative to the control group (EMM=
101.29, SE = 4.78).
Table 2 shows the correlation of mRNA transcripts
with ADI-R scores. We have adjusted the P values using
the Holm-Bonferroni sequential correction for multiple
comparisons. We did not find any significant correlation
of ERα, ERβ, and CYP19A1 mRNA levels with any of
the ADI-R scores.
Decrease in mRNA levels of ER co-activators (SRC-1, CBP
and P/CAF), but no change in ER co-repressors (SMRT and
nCoR) in the middle frontal gyrus of ASD subjects
Postmortem interval, storage time, sample pH, and RNA
integrity number were entered as covariates in the
model to analyze SRC-1 mRNA data. None of the covar-
iates in the model demonstrated a significant main effect
when they were entered in the model with affection sta-
tus. The predicted main effect of affection status on
SRC-1 expression was statistically significant (Figure 2A)e in ERα mRNA in the middle frontal gyrus of ASD subjects.
RNA in the ASD subjects. (C) CYP19A1 mRNA levels were significantly
the values were normalized to the geometric mean of two control












nCoR r –0.021 –0.202 0.479 –0.791 0.063
P 0.961 0.745 0.277 0.019 0.893
Adjusted P 1.000 1.000 1.000 0.095 1.000
SMRT r 0.013 –0.090 –0.258 –0.489 –0.640
P 0.976 0.866 0.576 0.219 0.122
Adjusted P 1.000 1.000 1.000 0.876 0.610
ER co-activators
CBP r –0.549 0.117 0.023 –0.261 –0.718
P 0.126 0.825 0.956 0.498 0.045
Adjusted P 0.504 1.000 1.000 1.000 0.225
P/CAF r –0.126 0.540 –0.319 0.515 –0.459
P 0.747 0.268 0.441 0.156 0.253
Adjusted P 1.000 1.000 1.000 0.780 1.000
TIF-2 R –0.103 0.687 –0.217 0.536 –0.325
P 0.792 0.132 0.606 0.137 0.432
Adjusted P 1.000 0.660 1.000 0.660 1.000
SRC-1 r –0.109 0.065 –0.876 0.294 –0.774
P 0.798 0.917 0.010 0.480 0.041
Adjusted P 1.000 1.000 0.049 1.000 0.164
AIB-1 r 0.274 0.200 0.099 −0.582 −0.000
P 0.475 0.703 0.814 0.099 0.999
Adjusted P 1.000 1.000 1.000 0.495 1.000
Estrogen receptor
ERα r 0.081 –0.210 0.265 –0.157 0.505
P 0.848 0.735 0.566 0.710 0.248
Adjusted P 1.000 1.000 1.000 1.000 1.000
ERβ r 0.112 –0.203 0.192 –0.215 0.316
P 0.791 0.743 0.680 0.610 0.489
Adjusted P 1.000 1.000 1.000 1.000 1.000
Enzyme
CYP19A1 r 0.405 –0.746 –0.143 –0.227 0.148
P 0.320 0.148 0.760 0.589 0.751
Adjusted P 0.740 1.000 1.000 1.000 1.000
ADI-R scores were available for only 9 of the 13 ASD subjects. Adjusted P denotes P values adjusted using the Holm-Bonferroni sequential correction for multiple
comparisons; r, Pearson correlation; P, level of significance. Bolded text indicates significant P values.
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cant reduction in SRC-1 mRNA (34% decrease) in the mid-
dle frontal gyrus of subjects with ASD (EMM=63.33, SE =
6.26) as compared to controls (EMM= 95.85, SE = 6.26).
The predicted main effect of affection status on CBP
mRNA was statistically significant, when postmortem
interval, storage time, sample pH, and RNA integrity num-
ber were entered as covariates in the model (Figure 2B)
[F(1, 18) = 53.15, P <0.0001, η2p = 0.747]. None of thecovariates in the model achieved statistical significance.
Overall, subjects with ASD (EMM= 21.86, SE = 6.65)
demonstrated much lower expression (77% decrease) of
CBP than the control group (EMM= 95.64, SE = 6.33).
Data on P/CAF mRNA was analyzed by considering post-
mortem interval, storage time, sample pH, and RNA in-
tegrity number as covariates in the model. However, none
of these covariates remained significant predictors when
they were entered into the model with affection status as
Figure 2 Decrease in mRNA levels of ER co-activators (SRC-1, CBP, and P/CAF), but no change in ER co-repressors (SMRT and nCoR) in
the middle frontal gyrus of ASD subjects. (A–E) Normalized mRNA expression of ER co-activators: (A) SRC-1, (B) CBP, (C) P/CAF, (D) TIF-2, and
(E) AIB-1. (F and G) Normalized mRNA expression of ER co-repressors: (F) SMRT and (G) nCoR. mRNA levels were determined by qRT-PCR, and
the values were normalized to the geometric mean of two control genes (GAPDH and β-actin). ***P <0.001 vs. controls.
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tus on P/CAF expression was found significant (Figure 2C)
[F(1, 18) = 33.53, P <0.0001, η2p = 0.651]. Moreover, a sig-
nificant reduction in P/CAF mRNA expression (52% de-
crease) was found in the middle frontal gyrus of subjects
with ASD (EMM= 47.47, SE = 5.71) as compared to con-
trols (EMM= 97.80, SE = 5.44). Storage time, sample pH,
and RNA integrity number were included in the model as
covariates to analyze the mRNA data on TIF-2. Among
these covariates, storage time [F(1, 20) = 4.70, P = 0.042,
η2p = 0.19] and sample pH [F(1, 20) = 4.32, P = 0.05, η
2
p =
0.18] remained significant covariates in the model. The
predicted main effect of affection status on TIF-2 expres-
sion did not achieve statistical significance (Figure 2D)
[F(1, 20) = 1.49, P= 0.236, η2p = 0.07]. Similarly, no significant
effect of affection status was observed on AIB-1 mRNA ex-
pression (Figure 2E) ([F(1, 20) = 1.37, P = 0.264, η2p = 0.06].
Next, we examined whether the mRNA levels of ER co-
repressors (SMRT and nCoR) are altered in the postmor-
tem brain tissues of subjects with ASD. With postmorteminterval and storage time entered as covariates in the
model, the predicted main effect of affection status on
SMRT expression was not statistically significant (Figure 2F)
[F(1, 17) = 0.013, P = 0.91, η2p = 0.001]. We found that stor-
age time [F(1, 17) = 7.51, P = 0.014, η2p = 0.306] remained a
statistically significant covariate in this model. Data on
nCoR mRNA was analyzed by considering postmortem
interval, storage time, sample pH, and RNA integrity num-
ber as covariates in the model. No main effect of affection
status was found on nCoR expression (Figure 2G) [F(1,
17) = 0.046, P = 0.83, η2p = 0.003]. Storage time [F(1, 17) =
9.59, P = 0.007, η2p = 0.361] was the only statistically sig-
nificant covariate found in this model.
We observed some significant associations between the
co-factors and the ADI-R scores in the subjects with ASD
(Table 2). SRC-1 mRNA was negatively correlated with
non-verbal communication (r = −0.876, P = 0.01) and ab-
normality of development (r = −0.774, P = 0.041) scores. A
significant negative correlation was found between CBP
mRNA and abnormality of development score (r = −0.718,
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associated with stereotyped behavior score (r = −0.791,
P = 0.019).
Correlations between mRNA expression of ERs, CYP19A1,
and co-factors in the middle frontal gyrus of study subjects
We used Spearman’s correlation to examine the relation-
ships between mRNA expression of ERs, CYP19A1, and
co-factors in the middle frontal gyrus of the study subjects.
Additional file 3: Table S3 depicts the correlations between
the mRNA transcripts. ERα was positively correlated with
ERβ and CYP19A1 mRNA levels. A large positive cor-
relation was observed between ERβ and CYP19A1. In
addition, ERβ was positively correlated with SRC–1, P/
CAF, and CBP. Similarly, CYP19A1 was positively corre-
lated with SRC1, P/CAF, and CBP. We also found signifi-
cant correlations in the mRNA levels between the co-
factors. Positive associations were found between SRC1
and P/CAF, CBP, TIF-2, SMRT, or nCoR. TIF-2 was po-
sitively correlated with P/CAF and CBP. In addition, we
observed positive correlations between P/CAF and CBP
mRNA levels, and CBP with SMRT expression. Interest-
ingly, a significant positive correlation was also found in
the mRNA levels between the co-repressors SMRT and
nCOR. We did not find any significant correlationFigure 3 Decrease in ERβ and CYP19A1 protein levels in the middle f
were determined by western blot analysis. The upper panels show represe
and the lower panels represent fold-change in normalized ERα, ERβ, and C
*P <0.05 vs. controls.between AIB-1 and ERs, CYP19A1, or other co-factors ex-
amined in this study.Decrease in ERβ and CYP19A1 protein levels in the
middle frontal gyrus of ASD subjects
Given that we found significant reductions in ERβ and
CYP19A1 mRNA levels in the middle frontal gyrus of sub-
jects with ASD, we next determined the expression of the
ERα, ERβ, and CYP19A1 at the protein level. We did not
find any significant change in ERα protein levels in the
middle frontal gyrus of subjects with ASD as compared to
controls (Figure 3A). We found a significant reduction in
ERβ protein (Figure 3B; P <0.05) and CYP19A1 (Figure 3C;
P <0.05) levels in the middle frontal gyrus of subjects with
ASD as compared to controls. Next, we examined whether
the co-factors whose levels were altered in the ASD inter-
act with ERβ in the brain samples. We performed immu-
noprecipitation assays to determine possible conjugation
of P/CAF, SRC-1, and CBP with ERβ in the middle frontal
gyrus of control subjects, and each of these immunopre-
cipitates was examined for co-purification of ERβ by
western blot. ERβ was detected in P/CAF, SRC-1, or
CBP immunoprecipitates, but not in the control IgG
(Additional file 4: Figure S1).rontal gyrus of ASD subjects. ERα, ERβ, and CYP19A1 protein levels
ntative autoradiogram of (A) ERα, (B) ERβ, or (C) CYP19A1 and GAPDH,
YP19A1 protein levels, respectively. Results are mean ± SEM vs. controls.
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We have found, for the first time, alterations in ERβ tran-
scriptional regulation in the brain of ASD subjects. We
also report a significant decrease in CYP19A1 expression
in ASD subjects. The above changes were associated with
alterations in ER co-activators in the same study subjects.
We did not find a significant difference in ERα expression
between ASD and controls. Together, these findings sug-
gest alterations in ER signaling in ASD.
The decrease in ERβ mRNA and protein expression in
the middle frontal gyrus of ASD subjects found in this
study is consistent with the increasing evidence for the
role of estrogen signaling in the etiology of ASD. A sig-
nificant association of the ERβ gene with autism traits as
measured by the Autism Spectrum Quotient and the
Empathy Quotient has been reported in ASD subjects
[14]. ERβ is abundantly expressed in the cortex [22].
Moreover, ERβ plays an important role in neurodevelop-
ment, and ERβ knockout, but not ERα knockout mice
show defects of neuronal migration [23]. It is known
that ERα and ERβ have distinct tissue expression pro-
files, and have different cellular functions [22-24]. ERα is
involved in mediating estrogen action on reproductive
organs and reproductive behavior, whereas ERβ is known
to mediate some of the effects of estrogens on behaviors
that are not specifically associated with reproduction,
such as locomotor activity, fear responses, anxiety, and
learning [15]. ERβ knockdown has been shown to abol-
ish E2-induced reductions in depressive behavior in mice
[25-27]. Moreover, administration of ERβ agonist or
selective ligand has been shown to reduce anxiety-type
behavior [27] and depressive behavior [28] in rats. Acti-
vation of ERβ with the specific agonist WAY-200070 in
cortical neurons results in increased spine density and
PSD-95 (postsynaptic density-95) accumulation in mem-
brane [29]. Together, these results suggest that ERβ-
mediated mechanism(s) are important for E2-induced
neuronal plasticity.
The decrease in ERβ expression found in the ASD
subjects might be the result of transcriptional regulation,
either through methylation or by the regulation of genes
of specific transcription factors binding to the ERβ pro-
moter. Hypermethylation of the ERβ promoter is associ-
ated with a marked decrease in ERβ mRNA expression
[30]. It is known that estrogen binds to ER leading to a
conformational change in ER. The estrogen-ER complex
can bind directly to DNA via an estrogen responsive
element or become attached to a transcription factor
[24]. It recruits a variety of co-regulators that result in
the activation or repression of target genes by modifying
chromatin structure. The p160/SRC (steroid receptor
co-activator) family is one of the most studied classes of
co-activators [31]. Among the co-activators, SRC-1 and
CBP exhibit autonomous histone acetyltransferase activitythat promotes efficient transcription. In contrast, in the
absence of ligands, ER associates with co-repressors nCoR
or SMRT to mediate transcriptional repression of target
genes through the histone deacetylase activity of the co-
repressors [32-34]. The present study revealed a novel
finding that ERβ expression levels correlated with ER co-
activators, SRC-1, P/CAF, and CBP. Moreover, we
observed that the above co-factors interact with ERβ in
human middle frontal gyrus. It is known that ERβ can
antagonize ERα-dependent transcription in cells [35]. In
addition, ERβ and its variant, ERβ2, have been shown to
increase the proteolytic degradation of ERα [36]. Thus, it
is possible that the changes in the expression levels of ERs
and co-factors observed in our study might influence the
estrogen receptor signaling machinery and might play im-
portant roles in the pathophysiology of ASD.
Our findings demonstrate that CYP19A1 expression is
significantly lower in the brain of ASD subjects. Earlier
studies have reported the expression of CYP19A1, the
key enzyme required for estrogen production, in the cor-
tex [37]. Furthermore, CYP19A1 is enriched at synapses
and localizes to presynaptic structures in cortical neu-
rons [29], suggesting that brain-synthesized estrogen
plays an important role in neuronal function [38]. The
decrease in CYP19A1 could lead to reduced conversion
of testosterone to estradiol resulting in increased levels
of testosterone as observed in ASD subjects [39]. Our
data is in agreement with a previous finding on reduced
aromatase protein levels in the frontal cortex of ASD
subjects [40]. An earlier genetic study has reported asso-
ciation between androgen receptor and ASD, suggesting
an important role of androgen signaling in ASD [41].
Further studies should examine the mRNA and protein
levels of androgen receptors in the brain samples from
ASD and control subjects, and such information would
be helpful to better understand the relationship between
estrogen-related and testosterone-related signaling path-
ways in ASD.
Conclusions
We have identified dysregulation of ERβ, CYP19A1, and
co-activators associated with ER signaling in the middle
frontal gyrus of ASD subjects with a significant associ-
ation between these molecules. Our data suggest that a
coordinated regulation of ER signaling molecules plays
an important role in ER signaling in the brain, and that
this network may be impaired in subjects with ASD. Al-
though we found a large, significant association between
the co-factor mRNA transcripts (SRC-1, CBP, and nCoR)
and ADI-R scores in ASD subjects, its implication is
unclear. Moreover, the robust reduction found in CBP
mRNA expression in ASD subjects needs further inves-
tigation. CBP is known to be associated with other ster-
oid receptors, including progesterone receptor, thyroid
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portant to examine whether the complex formation of
ERβ with CBP is indispensible for ER-dependent neur-
onal plasticity and ASD-like behavior. Moreover, the
present data was collected in a relatively smaller number
of study subjects, which needs further investigation
using large samples before a conclusion can be drawn.
Since brain tissue from individuals with ASD is quite
scarce, lymphoblastoid cell lines that are banked for
ASD cohorts (though there are several limitations in-
cluding difference in tissue type and difficulties in trans-
formation procedure) could provide a large sample of
biological material to understand the pathophysiology
of ASD. Future studies will investigate the mechanism
of regulation of ERβ in ASD, which might lead to a bet-
ter understanding of the pathophysiology and provide
new avenues of treatment of this disorder.
Availability of supporting data
The data sets supporting the results of this article are in-
cluded within the article and its additional files.
Additional files
Additional file 1: Table S1. List of primers used in the qRT-PCR.
Additional file 2: Table S2. Correlations of mRNA transcripts with
confounding variables.
Additional file 3: Table S3. Correlations between mRNA transcripts.
Additional file 4: Figure S1. ERβ is associated with the co-factors,
P/CAF, SRC1, or CBP. Lysates from postmortem middle frontal gyrus of
control subjects were subjected to immunoprecipitation (IP) using a
co-factor antibody followed by western blotting (WB) with the ERβ or
co-factor antibody. A separate IP assay was performed for (A) P/CAF,
(B) SRC1, or (C) CBP. Lysate represents 10% of the amount used in the IP.
IgG, IgG control.
Abbreviations
ADI-R: Autism diagnostic interview revised; AIB-1: Amplified in breast 1;
ASD: Autism spectrum disorders; CBP: CREB-binding protein;
CYP19A1: Cytochrome P450, Family 19, Subfamily A, Polypeptide 1;
EMM: Estimated marginal means; ER: Estrogen receptor; ERα: Estrogen
receptor alpha; ERβ: Estrogen receptor beta; GAPDH: Glyceraldehyde
3-phosphate dehydrogenase; nCoR: Nuclear receptor co-repressor 1;
P/CAF: p300/CREB-binding protein-associated protein; SE: Standard error;
SMRT: Silencing mediator of retinoid and thyroid hormone receptors;
SRC-1: Steroid receptor co-activator 1; TIF-2: Transcriptional mediators/
intermediary factor 2.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AC and RT carried out the gene expression studies. AC performed the
protein analysis. AOA carried out the statistical analysis and helped to draft
the manuscript. AP designed the study and wrote the manuscript. All
authors read and approved the final manuscript.
Acknowledgements
The authors would like to thank Diya Peter for her technical assistance.
Human postmortem samples were obtained from the NICHD Brain and
Tissue Bank for Developmental Disorders at the University of Maryland,Baltimore, MD, USA. The Bank is funded by NIH Contract No.
#HHSN275200900011C, Ref. No. NO1-HD-9-0011.
Author details
1Department of Psychiatry and Health Behavior, Medical College of Georgia,
Georgia Regents University, 997 St. Sebastian Way, Augusta, GA 30912, USA.
2Department of Neuroscience and Regenerative Medicine, Medical College
of Georgia, Georgia Regents University, 997 St. Sebastian Way, Augusta, GA
30912, USA.
Received: 9 May 2014 Accepted: 6 August 2014
Published: 9 September 2014
References
1. Gillberg C, Cederlund M, Lamberg K, Zeijlon L: Brief report: “the autism
epidemic”: the registered prevalence of autism in a Swedish urban area.
J Autism Dev Disord 2006, 36(3):429–435.
2. Auyeung B, Knickmeyer R, Ashwin E, Taylor K, Hackett G, Baron-Cohen S:
Effects of fetal testosterone on visuospatial ability. Arch Sex Behav 2012,
41(3):571–581.
3. Pfaff DW, Rapin I, Goldman S: Male predominance in autism:
neuroendocrine influences on arousal and social anxiety. Autism Res
2011, 4(3):163–176.
4. Amin Z, Canli T, Epperson CN: Effect of estrogen–serotonin interactions
on mood and cognition. Behav Cogn Neurosci Rev 2005, 4:43–58.
5. Berman KF, Schmidt PJ, Rubinow DR, Danaceau MA, Van Horn JD, Esposito G,
Ostrem JL, Weinberger DR: Modulation of cognition-specific cortical activity
by gonadal steroids: a positron-emission tomography study in women.
Proc Natl Acad Sci U S A 1997, 94:8836–8841.
6. Mueller SO, Korach KS: Estrogen receptors and endocrine diseases:
lessons from estrogen receptor knockout mice. Curr Opin Pharmacol 2001,
1:613–619.
7. Herynk MH, Fuqua SA: Estrogen receptor mutations in human disease.
Endocr Rev 2004, 25:869–898.
8. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M: Cofactor dynamics and
sufficiency in estrogen receptor-regulated transcription. Cell 2000,
103(6):843–852.
9. Mendelsohn ME, Karas RH: Rapid progress for non-nuclear estrogen
receptor signaling. J Clin Invest 2010, 120(7):2277–2279.
10. Östlund H, Keller E, Hurd YL: Estrogen receptor gene expression in
relation to neuropsychiatric disorders. Ann N Y Acad Sci 2003, 1007:54–63.
11. Österlund MK, Hurd YL: Estrogen receptors in the human forebrain and
the relation to neuropsychiatric disorders. Prog Neurobiol 2001, 64:251–267.
12. Herrington DM, Howard TD, Hawkins GA, Reboussin DM, Xu J, Zheng SL,
Brosnihan KB, Meyers DA, Bleecker ER: Estrogen-receptor polymorphisms and
effects of estrogen replacement on high-density lipoprotein cholesterol in
women with coronary disease. N Engl J Med 2002, 346:967–974.
13. Bodo C, Rissman EF: New roles for estrogen receptor beta in behavior
and neuroendocrinology. Front Neuroendocrinol 2006, 27(2):217–232.
14. Chakrabarti B, Dudbridge F, Kent L, Wheelwright S, Hill-Cawthorne G, Allison
C, Banerjee-Basu S, Baron-Cohen S: Genes related to sex steroids, neural
growth, and social-emotional behavior are associated with autistic traits,
empathy, and Asperger syndrome. Autism Res 2009, 2(3):157–177.
15. Krezel W, Dupont S, Krust A, Chambon P, Chapman PF: Increased anxiety
and synaptic plasticity in estrogen receptor beta -deficient mice. Proc
Natl Acad Sci U S A 2001, 98(21):12278–12282.
16. Carper RA, Courchesne E: Localized enlargement of the frontal cortex in
early autism. Biol Psychiatry 2005, 57(2):126–133.
17. Barendse EM, Hendriks MP, Jansen JF, Backes WH, Hofman PA, Thoonen G,
Kessels RP, Aldenkamp AP: Working memory deficits in high-functioning
adolescents with autism spectrum disorders: neuropsychological and
neuroimaging correlates. J Neurodev Disord 2013, 5(1):14.
18. Zikopoulos B, Barbas H: Altered neural connectivity in excitatory and
inhibitory cortical circuits in autism. Front Hum Neurosci 2013, 7:609.
19. Goldstein JM, Seidman LJ, Horton NJ, Makris N, Kennedy DN, Caviness VS Jr,
Faraone SV, Tsuang MT: Normal sexual dimorphism of the adult human
brain assessed by in vivo magnetic resonance imaging. Cereb Cortex
2001, 11(6):490–497.
20. Guo L, Hou X, Dilimina Y, Wang B: Expression of ERβ, ERα and Her-2 and
distribution of molecular subtypes in Uygur and Han patients with
breast cancer. Exp Ther Med 2014, 7(5):1077–1082.
Crider et al. Molecular Autism 2014, 5:46 Page 10 of 10
http://www.molecularautism.com/content/5/1/4621. Tam A, Wadsworth S, Dorscheid D, Man SF, Sin DD: Estradiol increases
mucus synthesis in bronchial epithelial cells. PLoS One 2014, 9(6):e100633.
22. Mitra SW, Hoskin E, Yudkovitz J, Pear L, Wilkinson HA, Hayashi S, Pfaff DW,
Ogawa S, Rohrer SP, Schaeffer JM, McEwen BS, Alves SE: Immunolocalization
of estrogen receptor beta in the mouse brain: comparison with estrogen
receptor alpha. Endocrinology 2003, 144:2055–2067.
23. Wang L, Andersson S, Warner M, Gustafsson JA: Estrogen receptor (ER)beta
knockout mice reveal a role for ERbeta in migration of cortical neurons
in the developing brain. Proc Natl Acad Sci U S A 2003, 100(2):703–708.
24. Behl C: Oestrogen as a neuroprotective hormone. Nat Rev Neurosci 2002,
3:433–442.
25. Rocha BA, Fleischer R, Schaeffer JM, Rohrer SP, Hickey GJ: 17β-estradiol-
induced antidepressant-like effect in the forced swim test is absent in
estrogen receptor-β knockout (BERKO) mice. Psychopharmacology (Berl)
2005, 179:637–643.
26. Weiser MJ, Foradori CD, Handa RJ: Estrogen receptor β in the brain: from
form to function. Brain Res Rev 2008, 57:309–320.
27. Weiser MJ, Wu TJ, Handa RJ: Estrogen receptor-β agonist diarylpropionitrile:
biological activities of R- and S-enantiomers on behavior and hormonal
response to stress. Endocrinology 2009, 150:1817–1825.
28. Walf AA, Frye CA: Administration of estrogen receptor β-specific selective
estrogen receptor modulators to the hippocampus decrease anxiety and
depressive behavior of ovariectomized rats. Pharmacol Biochem Behav
2007, 2007(86):407–414.
29. Srivastava DP, Woolfrey KM, Liu F, Brandon NJ, Penzes P: Estrogen receptor
β activity modulates synaptic signaling and structure. J Neurosci 2010,
30(40):13454–13460.
30. Nojima D, Li LC, Dharia A, Perinchery G, Ribeiro-Filho L, Yen TS, Dahiya R:
CpG hypermethylation of the promoter region inactivates the estrogen
receptor-beta gene in patients with prostate carcinoma. Cancer 2001,
92(8):2076–2083.
31. Lanz RB, McKenna NJ, Onate SA, Albrecht U, Wong J, Tsai SY, Tsai MJ,
O'Malley BW: A steroid receptor coactivator, SRA, functions as an RNA
and is present in an SRC-1 complex. Cell 1999, 97(1):17–27.
32. Shibata H, Spencer TE, Onate SA, Jenster G, Tsai SY, Tsai MJ, O’Malley BW:
Role of co-activators and co-repressors in the mechanism of steroid/
thyroid receptor action. Recent Prog Horm Res 1997, 52:141–164.
33. Torchia J, Glass C, Rosenfeld MG: Co-activators and co-repressors in the
integration of transcriptional responses. Curr Opin Cell Biol 1998, 10:373–383.
34. Parker MG: Transcriptional activation by oestrogen receptors. Biochem Soc
Symp 1998, 63:45–50.
35. Matthews J, Gustafsson JA: Estrogen signaling: a subtle balance between
ER alpha and ER beta. Mol Intervent 2003, 3:281–292.
36. Matthews J, Wihlen B, Tujague M, Wan J, Strom A, Gustafsson JÅ: Estrogen
receptor (ER) beta modulates ER-alpha-mediated transcriptional
activation by altering the recruitment of c-Fos and c-Jun to
estrogen-responsive promoters. Mol Endocrinol 2006, 20:534–543.
37. Yague JG, Muñoz A, de Monasterio-Schrader P, Defelipe J, Garcia-Segura LM,
Azcoitia I: Aromatase expression in the human temporal cortex.
Neuroscience 2006, 138(2):389–401.
38. Balthazart J, Ball GF: Is brain estradiol a hormone or a neurotransmitter?
Trends Neurosci 2006, 29(5):241–249.
39. Baron-Cohen S, Lombardo MV, Auyeung B, Ashwin E, Chakrabarti B,
Knickmeyer R: Why are autism spectrum conditions more prevalent in
males? PLoS Biol 2011, 9(6):e1001081.
40. Sarachana T, Xu M, Wu R-C, Hu VW: Sex hormones in autism: androgens
and estrogens differentially and reciprocally regulate RORA, a novel
candidate gene for autism. PLoS One 2011, 6(2):e17116.
41. Henningsson S, Jonsson L, Ljunggren E, Westberg L, Gillberg C, Råstam M,
Anckarsäter H, Nygren G, Landén M, Thuresson K, Betancur C, Leboyer M,
Gillberg C, Eriksson E, Melke J: Possible association between the androgen
receptor gene and autism spectrum disorder. Psychoneuroendocrinology
2009, 34(5):752–761.
doi:10.1186/2040-2392-5-46
Cite this article as: Crider et al.: Dysregulation of estrogen receptor beta
(ERβ), aromatase (CYP19A1), and ER co-activators in the middle frontal
gyrus of autism spectrum disorder subjects. Molecular Autism 2014 5:46.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
